13
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Cystoid Macular Edema following Treatment with Nanoparticle Albumin-Bound Paclitaxel and Atezolizumab for Metastatic Breast Cancer

      case-report

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cystoid macular edema (CME) is a rare side effect associated with chemotherapy. Although the development of CME has been reported to occur following treatment with taxane drugs, such as nanoparticle albumin-bound paclitaxel (Nab-PTX), the occurrence of CME with treatment with atezolizumab has not yet been reported. Here, we report the case of a 49-year-old woman who developed CME 19 months into chemotherapy with Nab-PTX and atezolizumab. Improvement was not achieved with steroid injections into the Tenon’s sac, and Nab-PTX and atezolizumab treatments were ceased. One month later, there was subjective improvement in her symptoms. Although many reports have indicated that cessation of chemotherapy has successfully improved CME, a specific treatment for CME has not yet been established. Clinicians should be aware of the ophthalmologic side effects and offer immediate treatment if symptoms develop.

          Related collections

          Most cited references32

          • Record: found
          • Abstract: found
          • Article: not found

          Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

          Unresectable locally advanced or metastatic triple-negative (hormone-receptor-negative and human epidermal growth factor receptor 2 [HER2]-negative) breast cancer is an aggressive disease with poor outcomes. Nanoparticle albumin-bound (nab)-paclitaxel may enhance the anticancer activity of atezolizumab.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

            The therapeutic options for patients with noninvasive or invasive breast cancer are complex and varied. These NCCN Clinical Practice Guidelines for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory breast cancer, and management of breast cancer during pregnancy. The content featured in this issue focuses on the recommendations for overall management of ductal carcinoma in situ and the workup and locoregional management of early stage invasive breast cancer. For the full version of the NCCN Guidelines for Breast Cancer, visit NCCN.org .
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found
              Is Open Access

              First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis

                Bookmark

                Author and article information

                Journal
                Case Rep Oncol
                Case Rep Oncol
                CRO
                CRO
                Case Reports in Oncology
                S. Karger AG (Basel, Switzerland )
                1662-6575
                16 October 2023
                Jan-Dec 2023
                16 October 2023
                : 16
                : 1
                : 1121-1128
                Affiliations
                [a ]Department of Breast Surgery, Hiroshima General Hospital, Hiroshima, Japan
                [b ]Department of Surgery, Yamane Clinic, Hiroshima, Japan
                [c ]Department of Ophthalmology, Koura Eye Clinic, Hiroshima, Japan
                [d ]Department of Breast Surgery, Hatsukaichi Breast Care Clinic, Hiroshima, Japan
                Author notes
                Correspondence to: Hiroaki Yamane, basara014@ 123456yahoo.co.jp
                Article
                533999
                10.1159/000533999
                10601834
                37900858
                d841f772-72c3-4d80-82f4-aef1bed35b68
                © 2023 The Author(s). Published by S. Karger AG, Basel

                This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) ( http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.

                History
                : 6 April 2023
                : 24 August 2023
                : 2023
                Page count
                Figures: 1, Tables: 2, References: 32, Pages: 8
                Funding
                No funding was received for this study.
                Categories
                Case Report

                Oncology & Radiotherapy
                atezolizumab,breast cancer,cystoid macular edema,nanoparticle albumin-bound paclitaxel

                Comments

                Comment on this article